Coagulation factor VIII

• The material for testing is blood.
• The patient must not be undergoing treatment with high molecular weight heparin.
• The patient does not need to fast.

Samples brought from outside are not accepted for testing.

Factor VIII (FVIII, antihemophilic factor A, platelet factor I).
Factor VIII coagulation testing is performed in the diagnosis of venous thromboembolism of unknown cause, in the diagnosis of FVIII deficiency, hemophilia, in cases of abnormal bleeding, and in cases of abnormal aPTT results.
FVIII is produced in the liver, spleen, placenta, and megakaryocytes as an inactive form. Activation occurs under the influence of thrombin and factor Xa. It is involved in the stabilization of cross-linked fibrin. Factor VIII circulates in a complex with von Willebrand factor, which may be associated with arterial thrombosis.
Reduced FVIII activity occurs in:
• states of increased fibrinolysis
• von Willebrand disease
• treatment with valproic acid
• hemophilia A (congenital FVIII deficiency)
• acquired hemophilia (acquired FVIII deficiency).
The most common of the acquired coagulation factor inhibitors (5 cases per 1 million), an acquired FVIII inhibitor occurs as a life-threatening bleeding diathesis in women in the first weeks after pregnancy, in cancer and autoimmune diseases, and after surgery, in people > 60 years of age.
Increased FVIII activity occurs in:
• liver damage
• cancer
• acute and chronic infections
• inflammatory conditions
• major trauma, surgical procedures
• nephrotic syndrome
• glucocorticosteroid therapy
• acute phase of venous or arterial thrombosis

Enter one-time code: Show
Invalid code entered. Please try again.